HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY DERIVED FROM AN ALTERNATIVE DONOR BY USING NEW TRANSPLANT ENGINEERING TECHNOLOGIES

Cover Page


Cite item

Full Text

Abstract

Analysis of the results of hematopoietic stem cell transplantation (HSCT) derived from alternative donors in patients with primary immunodeficiency syndromes. 110 HSCTs for patients with PIDs derived from alternative donors (unrelated, n = 85, haploidentical, t = 25) were performed at the Dmitry Rogachev National Medical Research Centre within 2012-2017 timeframe. In all cases, there were used conditioning regimes with reduced toxicity based on threosulfan TCRotP+/CD19+ depletion with immunomagnetic method were used as the basic cell transplant preparation. The cumulative probability of acute GVHD was 17% (95% CI 10-25) (n = 18); however, it should be noted that in 16 of 18 cases, an acute GVHD, stage II, was observed, showing a good response to the first line therapy; but acute GVHD, stage III, was documented only in 2 patients. Reactivation of cytomegalovirus infection remained one of the serious issues, with a cumulative probability of its reactivation reaching up to 50% and CMV visceral infection rate found in 15.4% cases. The conditioning regimen in patients with Wiskott-Aldrich syndrome by using granulocyte colony-stimulating factor and plerixafor demonstrated a full control over transplant dysfunction compared to control group.

Rate of immunological reconstitution upon inoculation of HSCT on the platform TCRotP+/CD19+ deletion did not differ in dynamics from that one after using undepleted HSCT together with native hematopoietic stem cell sources in a historical cohort. The overall survival probability for entire PID patient cohort was 84% (95% CI 77-92). No differences in patients transplanted from unrelated and haploidentical donors were revealed by assessing any of the studied parameters.

Introduction of new HSCT technologies allows us to dramatically minimize adverse outcomes of PIDs and opens new avenues for further research in cellular regulation of autoinflammatory oncological and infectious disorders resulting in lethal outcome in PID patients.

About the authors

D. N. Balashov

D. Rogachev National Medical Research Centre for Pediatric Hemtology, Oncology and Immunology

Author for correspondence.
Email: bala8@yandex.ru

Balashov Dmitry N. D. PhD, MD (Medicine), Professor, Head, Hematopoietic Stem Cell Transplantation Department No. 2

Phone: 7 (495) 221-66-40. 117997, Moscow, Samori Mashela str., 1

Russian Federation

M. A. Maschan

D. Rogachev National Medical Research Centre for Pediatric Hemtology, Oncology and Immunology

Email: fake@neicon.ru
Maschan M.A., PhD, MD (Medicine), Professor, Director, High School of Molecular and Experimental Medicine Russian Federation

A. Yu. Shcherbina

D. Rogachev National Medical Research Centre for Pediatric Hemtology, Oncology and Immunology

Email: fake@neicon.ru
Shcherbina A.Yu., PhD, MD (Medicine), Professor, Head, Сlinical Immunology Department, Deputy Director Russian Federation

A. G. Rumyantsev

D. Rogachev National Medical Research Centre for Pediatric Hemtology, Oncology and Immunology

Email: fake@neicon.ru
Rumyantsev A.G., PhD, MD (Medicine), Professor, President Russian Federation

References

  1. Балашов Д.Н., Гутовская Е.И., Козловская C.H., Радыгина С.А., Лаберко A.Л., Масчан А.А. Применение плериксафора и гранулоцитарногоколониестимулирующего фактора в кондиционировании перед трансплантацией гемопоэтических стволовых клеток у пациентов с синдромом Вискотта–Олдрича // Вопросы гематологии/онкологии и иммунопатологии в педиатрии, 2017. Т. 16, № 3. С. 55-58.
  2. Aversa F., Tabilio A., Velardi A., Cunningham I., Terenzi A., Falzetti F., Falzetti F., Ruggeri L., Barbabietola G., Aristei C., Latini P., Reisner Y., Martelli M.F. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N. Engl. J. Med., 1998, Vol. 339, no. 17, 1186-1193.
  3. Bach F., Albertini R., Joo P., Anderson J., Bortin M. Bone-marrow transplantation in a patient with the Wiskott–Aldrich syndrome. Lancet, 1968, Vol. 292, no. 7583, pp. 1364-1366.
  4. Bacigalupo A., Mordini N., Pitto A., Piaggio G., Podesta М., Benvenuto F., van Lint M.T., Valbonesi M., Lercari G., Carlier P., Lamparelli T., Gualandi F., Occhini D., Bregante S., Figari O., Soracco M., Vassallo F., de Stefan G. Transplantation of HLA-mismatched CD34+ selected cells in patients with advanced malignancies: severe immunodeficiency and related complications. Br. J. Haematol., 1997, Vol. 98, no. 3, pp. 760-766.
  5. Balashov D., Laberko A., Shcherbina A., Trakhtman P., Abramov D., Gutovskaya E., Kozlovskaya S., Shelikhova L., Novichkova G., Maschan М., Rumiantsev A., Maschan A. A Conditioning regimen with plerixafor is safe and improves the outcome of TCRaP++ and CD19+ cell-depleted stem cell transplantation in patients with Wiskott–Aldrich syndrome. Biol. Blood Marrow Transplant., 2018, Vol. 24, no. 7, pp. 1432-1440.
  6. Balashov D., Shcherbina A., Maschan М., Trakhtman P., Skvortsova Y., Shelikhova L., Laberko A., Livshits A., Novichkova G., Maschan A. Single-center experience of unrelated and haploidentical stem cell transplantation with TCRaP and CD19 depletion in children with primary immunodeficiency syndromes. Biol. Blood Marrow Transplant., 2015, Vol. 21, no. 11, pp. 1955-1962.
  7. Bertaina A., Merli P., Rutella S., Pagliara D., Bernardo M.E., Masetti R., Pende D., Falco M., Handgretinger R., Moretta F., Lucarelli B., Brescia L.P., Li Pira G., Testi M., Cancrini C., Kabbara N., Carsetti R., Finocchi A., Moretta A., Moretta L., Locatelli F. HLA-haploidentical stem cell transplantation after removal of αβ+ T and В cells in children with nonmalignant disorders. Blood, 2014, Vol. 124, no. 5, pp. 822-826.
  8. Bonneville М., O’Brien R.L., Born W.K. γδ T cell effector functions: a blend of innate programming and acquired plasticity. Nat. Rev. Immunol., 2010, Vol. 10, no. 7, pp. 467-478.
  9. Brodszki N., Turkiewicz D., Toporski J., Truedsson L., Dykes J. Novel treatment of severe combined immunodeficiency utilizing ex-vivo T-cell depleted haploidentical hematopoietic stem cell transplantation and CD45RA+ depleted donor lymphocyte infusions. Orphanet J. Rare Dis., 2016, Vol. 11, 5. doi: 10.1186/s13023-016-0385-3.
  10. de Koning J., van Bekkum D.W., Dicke K.A., Dooren L.J., van Rood J.J., Radi J. Transplantation of bonemarrow cells and fetal thymus in an infant with lymphopenic immunological deficiency. Lancet, 1969, Vol. 293, no. 7608, pp. 1223-1227.
  11. European Society for Immunodeficiencies. Registry Working Party Diagnosis criteria. Available at:https:// esid.org/Working-Parties/Registry-Working-Party/Diagnosis-criteria.
  12. Feuchtinger Т., Matthes-Martin S., Richard C., Lion Т., Fuhrer М., Hamprecht K., Handgretinger R., Peters C., Schuster F.R., Beck R., Schumm M., Lofti R., Jahn G., Lang P. Safe adoptive transfer of virus-specific T-cell immunity for the treatment of systemic adenovirus infection after allogeneic stem cell transplantation. Br. J. Haematol., 2006, Vol. 134, no. 1, pp. 64-76.
  13. Feuchtinger, Т., Opherk K., Bethge W.A., Topp M.S., Schuster F.R., Weissinger E.M., Mohty M., Or R., Maschan M., Schumm M., Hamprecht K., Handgretinger R., Lang P., Einsele H. Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation. Blood, 2010, Vol. 116, no. 20, pp. 4360-4367.
  14. Fischer A. Human primary immunodeficiency diseases. Immunity, 2007, Vol. 27, no. 6, pp. 835-845.
  15. Gatti R., Meuwissen H., Allen H., Hong R., Good R. Immunological reconstitution of sex-linked lymphopenic immunological deficiency. Lancet, 1968, Vol. 292, no. 7583, pp. 1366-1369.
  16. Handgretinger R. Negative depletion of CD3+ and TcRa+ T cells. Curr. Opin. Hematol., 2012, Vol. 19, no. 6, pp. 434-439.
  17. Locatelli F., Bauquet A., Palumbo G., Moretta F., Bertaina A. Negative depletion of α/β+ T cells and of CD19+ В lymphocytes: A novel frontier to optimize the effect of innate immunity in HLA-mismatched hematopoietic stem cell transplantation. Immunol. Lett., 2013, Vol. 155, no. 1-2, pp. 21-23.
  18. Modell V., Gee B., Lewis D.B., Orange J.S., Roifman C.M., Routes J.M., Sorenson R.U., Notarangelo L.D., Modell F. Global study of primary immunodeficiency diseases (PI) – diagnosis, treatment, and economic impact: an updated report from the Jeffrey Modell Foundation. Immunol. Res., 2011, Vol. 51, no. 1, pp. 61-70.
  19. Moratto D., Guiliani S., Bonlim C., Mazzolari E., Fischer A., Ochs H.D., Cant A.J., Thrasher A.J., Cowan M.J., Albert M.H., Small T., Pai S.Y., Haddad E., Lisa A., Hambelton S., Slatter M., Cavazzana-Calvo M., Mahlaoui N., Picard C., Torgerson T.R., Burroughs L., Koliski A., Neto J.Z., Porta F., Qasim W., Veys P., Kavanau K., Hoenig M., Schulz A., Friedrich W., Notarangelo L.D. Long-term outcome and lineage-specific chimerism in 194 patients with Wiskott–Aldrich syndrome treated by hematopoietic cell transplantation in the period 1980-2009: an international collaborative study. Blood, 2011, Vol. 118, no. 6, pp. 1675-1684.
  20. Ochs H.D., Filipovich A.H., Veys P., Cowan M.J., Kapoor N. Wiskott–Aldrich syndrome: diagnosis, clinical and laboratory manifestations, and treatment. Biol. Blood Marrow Transplant., 2009, Vol. 15, no. 1, pp. 84-90.
  21. Picard C., Al-Herz W., Bousfiha A., Casanova J.-L., Chatila Т., Conley M.E., Cunningham-Rundies C., Etzioni A., Holland S.M., Klein C., Nonoyama S., Ochs H.D., Oksenhendler E., Puck J.M., Sullivan K.E., Tang M.L., Franco J.L., Gaspar H.B. Primary immunodeficiency diseases: an update on the classification from the International Union of Immunological Societies Expert Committee for Primary Immunodeficiency 2015. J. Clin. Immunol., 2015, Vol. 35, no. 8, pp. 696-726.
  22. Rooney C.M., Ng C.Y., Loftin S., Smith C., Li C, Krance R., Brenner M.K., Heslop H.E. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet Lond. Engl., 1995, Vol. 345, no. 8941, pp. 9-13.
  23. Schumm M., Lang P., Bethge W., Faul C., Feuchtinger Т., Pfeiffer М., Vogel W., Huppert V., Handgretinger R. Depletion of T-cell receptor alpha/beta and CD19 positive cells from apheresis products with the CliniMACS device. Cytotherapy, 2013, Vol. 15, no. 10, pp. 1253-1258.
  24. Shah R.M., Elfeky R., Nademi Z., Qasim W., Amrolia P., Chiesa R., Rao K., Lucchini G., Silva J.M.F., Worth A., Barge D., Ryan D., Conn J., Cant A.J., Skinner R., Abd Hamid I.J., Flood T., Abinum M., Hambleton S., Gennery A.R., Veys P., Slatter M. T-cell receptor αβ+ and CD19+ cell-depleted haploidentical and mismatched hematopoietic stem cell transplantation in primary immune deficiency. Allergy Clin. Immunol., 2018, Vol. 141, no. 4, pp. 1417-1426.
  25. Slatter M.A., Brigham K., Dickinson A.M., Harvey H.L., Barge D., Jackson A., Bown N., Flood T.J., Cant A.J., Abinun M., Gennery A.R. Long-term immune reconstitution after anti-CD52-treated or anti-CD34-treated hematopoietic stem cell transplantation for severe T-lymphocyte immunodeficiency. J. Allergy Clin. Immunol., 2008, Vol. 121, no. 2, pp. 361-367.
  26. van Sambeek B., Flattery М., Mitchell R., de Abreu Lourenco R. Comparing the cost of preparing matched unrelated donor and TCR α+β+/CD19+ depleted donor material for pediatric hematopoietic stem cell transplants in Australia. Pediatr. Transplant. 2018, Vol. 22, no. 7, e13279. doi: 10.1111/petr.13279.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2020 Balashov D.N., Maschan M.A., Shcherbina A.Y., Rumyantsev A.G.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № 77 - 11525 от 04.01.2002.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies